Trabectedin-Ecteinascidin-743-DataSheet-生命科學(xué)試劑-MedChemExpress_第1頁(yè)
Trabectedin-Ecteinascidin-743-DataSheet-生命科學(xué)試劑-MedChemExpress_第2頁(yè)
Trabectedin-Ecteinascidin-743-DataSheet-生命科學(xué)試劑-MedChemExpress_第3頁(yè)
Trabectedin-Ecteinascidin-743-DataSheet-生命科學(xué)試劑-MedChemExpress_第4頁(yè)
全文預(yù)覽已結(jié)束

下載本文檔

版權(quán)說(shuō)明:本文檔由用戶提供并上傳,收益歸屬內(nèi)容提供方,若內(nèi)容存在侵權(quán),請(qǐng)進(jìn)行舉報(bào)或認(rèn)領(lǐng)

文檔簡(jiǎn)介

Hotline:400-820-3792Inhibitors?ScreeningLibraries?Proteinswww.MedChemETrabectedinCat.No.:HY-50936CASNo.:114899-77-3Synonyms:Ecteinascidin743;ET-743分?式:C??H??N?O??S分?量:761.84作?靶點(diǎn):ReactiveOxygenSpecies;Apoptosis作?通路:Immunology/Inflammation;MetabolicEnzyme/Protease;NF-κB;Apoptosis儲(chǔ)存?式:-20°C,protectfromlight,storedundernitrogen*該產(chǎn)品在溶液狀態(tài)不穩(wěn)定,建議您現(xiàn)?現(xiàn)配,即刻使?。溶解性數(shù)據(jù)體外實(shí)驗(yàn)DMSO:33.33mg/mL(43.75mM;Needultrasonic)MassSolvent1mg5mg10mgConcentration制備儲(chǔ)備液1mM1.3126mL6.5631mL13.1261mL5mM0.2625mL1.3126mL2.6252mL10mM0.1313mL0.6563mL1.3126mL請(qǐng)根據(jù)產(chǎn)品在不同溶劑中的溶解度,選擇合適的溶劑配制儲(chǔ)備液;該產(chǎn)品在溶液狀態(tài)不穩(wěn)定,建議您現(xiàn)?現(xiàn)配,即刻使?.體內(nèi)實(shí)驗(yàn)請(qǐng)根據(jù)您的實(shí)驗(yàn)動(dòng)物和給藥?式選擇適當(dāng)?shù)娜芙?案。以下溶解?案都請(qǐng)先按照InVitro?式配制澄的儲(chǔ)備液,再依次添加助溶劑:(為保證實(shí)驗(yàn)結(jié)果的可靠性,澄的儲(chǔ)備液可以根據(jù)儲(chǔ)存條件,適當(dāng)保存;體內(nèi)實(shí)驗(yàn)的?作液,建議您現(xiàn)?現(xiàn)配,當(dāng)天使?;以下溶劑前顯?的百分?指該溶劑在您配制終溶液中的體積占?;如在配制過(guò)程中出現(xiàn)沉淀、析出現(xiàn)象,可以通過(guò)加熱和/或超聲的?式助溶)1.請(qǐng)依序添加每種溶劑:10%DMSO>>90%(20%SBE-β-CDinsaline)Solubility:≥2.5mg/mL(3.28mM);Clearsolution2.請(qǐng)依序添加每種溶劑:10%DMSO>>90%cornoil1/3MasterofBioactiveMolecules—您?邊的抑制劑?師www.MedChemESolubility:≥2.5mg/mL(3.28mM);Clearsolution3.請(qǐng)依序添加每種溶劑:5%DMSO>>40%PEG300>>5%Tween-80>>50%salineSolubility:≥2.5mg/mL(3.28mM);ClearsolutionBIOLOGICALACTIVITY?物活性Trabectedin(Ecteinascidin743;ET-743)?種四氫異喹啉?物堿,具有有效的抗腫瘤活性。Trabectedin與DNA的?溝結(jié)合,阻斷應(yīng)激誘導(dǎo)的蛋?質(zhì)的轉(zhuǎn)錄,誘導(dǎo)DNA?架裂解和癌細(xì)胞凋亡(apoptosis),并增加MCF-7和MDA-MB-453細(xì)胞中ROS的?成。Trabectedin可?于軟組織?瘤和巢癌的研究。IC50&TargetIC50:0.1nM(MX-1cells),1.5nM(MCF7cells)and3.7nM(MCF7/DXRcells)[1]Reactiveoxygenspecies(ROS)[2]Apoptosis[2]體外研究Trabectedin(ET-743;10nM;24-72hours;MCF7cells)treatmentresultsincellaccumulationinlateStoG2phase[1].TrabectedininhibitscellgrowthofMX-1,MCF7andMCF7/DXRcellswithIC50valuesof0.1nM,1.5nMand3.7nM,respectively[1].Trabectedininducescytotoxicityandapoptosisinbothbreastcancercellsinatimeandconcentration-dependentmanner.Theexpressionlevelsofthedeathreceptorpathwaymolecules,TRAIL-R1/DR4,TRAIL-R2/DR5,FAS/TNFRSF6,TNFRI/TNFRSF1A,andFADDaresignificantlyincreasedby2.6-,3.1-,1.7-,11.2-and4.0-foldbyTrabectedintreatmentinMCF-7cells.InMDA-MB-453cells,themitochondrialpathwayrelatedpro-apoptoticproteinsBax,Bad,Cytochromec,Smac/DIABLO,andCleavedCaspase-3expressionsareinducedby4.2-,3.6-,4.8-,4.5-,and4.4-fold,andtheexpressionlevelsofanti-apoptoticproteinsBcl-2andBcl-XLarereducedby4.8-and5.2-foldinMDA-MB-453cells[2].InvitrotreatmentwithnoncytotoxicconcentrationsofTrabectedinselectivelyinhibitstheproductionofCCL2,CXCL8,IL-6,VEGF,andPTX3bymyxoidliposarcoma(MLS)primarytumorculturesand/orcelllines[3].CellCycleAnalysis[1]CellLine:MCF7cellsConcentration:10nMIncubationTime:24hours,48hours,72hoursResult:LedtopronouncedS-G2-Maccumulation.體內(nèi)研究Trabectedin(ET-743;30-50μg/kg;intravenousinjection;everythreedays;femaleathymicnudemice)treatmentincreasestheantitumoreffectsinnudemicebearingMX-1mammarycarcinomaxenograftswithoutincreasingtoxicity[1].Axenograftmousemodelofhumanmyxoidliposarcoma(MLS)showsmarkedreductionofCCL2,CXCL8,CD68+infiltratingmacrophages,CD31+tumorvessels,andpartialdecreaseofPTX3afterTrabectedintreatment[3].2/3MasterofBioactiveMolecules—您?邊的抑制劑?師www.MedChemEAnimalModel:Femaleathymicnudemicebearingthenu/nugene(5-6weeksold,18-20g)injectedwithMX-1cells[1]Dosage:30μg/kg,40μg/kg,50μg/kgAdministration:Intravenousinjection;everythreedaysResult:IncreasedtheantitumoreffectsinnudemicebearingMX-1mammarycarcinomaxenograftswithoutincreasingtoxicity.REFERENCES[1].TakahashiN,etal.Sequence-dependentsynergisticcytotoxicityofecteinascidin-743andNSC125973inhumanbreastcancercelllinesinvitroandinvivo.CancerRes.2002Dec1;62(23):6909-15.[2].GermanoG,etal.Antitumorandanti-inflammatoryeffectsoftrabectedinonhumanmyxoidliposarcomacells.CancerRes.2010Mar15;70(6):2235-44.[3].AtmacaH,etal.AdiverseinductionofapoptosisbytrabectedininMCF-7(HER2-/ER+)andMDA-MB-453(HER2+/ER-)breastcancercells.ToxicolLett.2013Jun20;221(2):128-136.

溫馨提示

  • 1. 本站所有資源如無(wú)特殊說(shuō)明,都需要本地電腦安裝OFFICE2007和PDF閱讀器。圖紙軟件為CAD,CAXA,PROE,UG,SolidWorks等.壓縮文件請(qǐng)下載最新的WinRAR軟件解壓。
  • 2. 本站的文檔不包含任何第三方提供的附件圖紙等,如果需要附件,請(qǐng)聯(lián)系上傳者。文件的所有權(quán)益歸上傳用戶所有。
  • 3. 本站RAR壓縮包中若帶圖紙,網(wǎng)頁(yè)內(nèi)容里面會(huì)有圖紙預(yù)覽,若沒(méi)有圖紙預(yù)覽就沒(méi)有圖紙。
  • 4. 未經(jīng)權(quán)益所有人同意不得將文件中的內(nèi)容挪作商業(yè)或盈利用途。
  • 5. 人人文庫(kù)網(wǎng)僅提供信息存儲(chǔ)空間,僅對(duì)用戶上傳內(nèi)容的表現(xiàn)方式做保護(hù)處理,對(duì)用戶上傳分享的文檔內(nèi)容本身不做任何修改或編輯,并不能對(duì)任何下載內(nèi)容負(fù)責(zé)。
  • 6. 下載文件中如有侵權(quán)或不適當(dāng)內(nèi)容,請(qǐng)與我們聯(lián)系,我們立即糾正。
  • 7. 本站不保證下載資源的準(zhǔn)確性、安全性和完整性, 同時(shí)也不承擔(dān)用戶因使用這些下載資源對(duì)自己和他人造成任何形式的傷害或損失。

最新文檔

評(píng)論

0/150

提交評(píng)論